SUSAN BOBULSKY, the Chief Commercial Officer of $ADPT, sold 5,000 shares of the company on 06-11-2026 for an estimated $95,000. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.2% of their shares of this class of stock. Following this trade, they now own 411,775 shares of this class of $ADPT stock.
$ADPT Insider Trading Activity
$ADPT insiders have traded $ADPT stock on the open market 83 times in the past 6 months. Of those trades, 0 have been purchases and 83 have been sales.
Here’s a breakdown of recent trading of $ADPT stock by insiders over the last 6 months:
- CHAD M ROBINS (CEO and Chairman) has made 0 purchases and 10 sales selling 1,365,756 shares for an estimated $20,533,233.
- JULIE RUBINSTEIN (President and COO) has made 0 purchases and 47 sales selling 949,407 shares for an estimated $13,371,111.
- HARLAN S ROBINS (Chief Scientific Officer) has made 0 purchases and 8 sales selling 557,287 shares for an estimated $7,697,737.
- FRANCIS LO (Chief People Officer) has made 0 purchases and 8 sales selling 331,971 shares for an estimated $5,351,938.
- MICHELLE RENEE GRIFFIN has made 0 purchases and 2 sales selling 63,438 shares for an estimated $949,203.
- SUSAN BOBULSKY (Chief Commercial Officer, MRD) has made 0 purchases and 3 sales selling 57,338 shares for an estimated $837,421.
- SHARON BENZENO (Chief Commercial Ofc Imm Med) sold 63,103 shares for an estimated $831,066
- KYLE PISKEL (Chief Financial Officer) has made 0 purchases and 4 sales selling 28,222 shares for an estimated $403,346.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ADPT Hedge Fund Activity
We have seen 153 institutional investors add shares of $ADPT stock to their portfolio, and 154 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,821,148 shares (-64.3%) from their portfolio in Q1 2026, for an estimated $39,157,534
- BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. added 2,688,081 shares (+inf%) to their portfolio in Q1 2026, for an estimated $37,310,564
- INVESCO LTD. added 2,216,595 shares (+248.8%) to their portfolio in Q4 2025, for an estimated $35,997,502
- MACQUARIE GROUP LTD removed 2,104,414 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $34,175,683
- JENNISON ASSOCIATES LLC removed 1,921,595 shares (-71.8%) from their portfolio in Q1 2026, for an estimated $26,671,738
- IRON TRIANGLE PARTNERS LP removed 1,820,915 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $29,571,659
- WELLINGTON MANAGEMENT GROUP LLP added 1,692,095 shares (+78.1%) to their portfolio in Q1 2026, for an estimated $23,486,278
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ADPT Revenue
$ADPT had revenues of $70.9M in Q1 2026. This is an increase of 35.14% from the same period in the prior year.
You can track ADPT financials on Quiver Quantitative's ADPT stock page.
You can access data on ADPT stock through the Quiver Quantitative API.
$ADPT Price Targets
Multiple analysts have issued price targets for $ADPT recently. We have seen 5 analysts offer price targets for $ADPT in the last 6 months, with a median target of $21.0.
Here are some recent targets:
- Tejas Savant from Morgan Stanley set a target price of $18.0 on 05/12/2026
- Mark Massaro from BTIG set a target price of $22.0 on 05/06/2026
- Subbu Nambi from Guggenheim set a target price of $21.0 on 05/06/2026
- Sebastian Sandler from JP Morgan set a target price of $19.0 on 05/06/2026
- Dan Brennan from TD Cowen set a target price of $21.0 on 05/06/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
